{"name":"NEMA Research, Inc.","slug":"nema-research-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cesamet™ (nabilone)","genericName":"Cesamet™ (nabilone)","slug":"cesamet-nabilone","indication":"Chemotherapy-induced nausea and vomiting (CINV)","status":"marketed"}]}],"pipeline":[{"name":"Cesamet™ (nabilone)","genericName":"Cesamet™ (nabilone)","slug":"cesamet-nabilone","phase":"marketed","mechanism":"Nabilone is a synthetic cannabinoid that mimics THC and binds to cannabinoid receptors in the central nervous system to reduce nausea and vomiting.","indications":["Chemotherapy-induced nausea and vomiting (CINV)","Post-operative nausea and vomiting (PONV)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxObkxuTXpZUWRJblFvdUl5VGxqdnRERDZRMml5am5LX0hYaXZaMjVJblUxalZValBpRGxLZjZMT0JYZWE4Wk1jRjhsa29WdEhsTDkzRTJ1TG9ZWXF2RFFnWTU0YjU0b0pnYmhlMHlLZGZscDlWZXpfQW5HMTB3b3h2d0ZxSjdHWVdCVURPbUJRRnFJQQ?oc=5","date":"2025-10-24","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Innocan Pharma to Present at the 2025 ThinkEquity Conference - Yahoo! Finance Canada","headline":"Innocan Pharma to Present at the 2025 ThinkEquity Conference - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFA4d3F6Uk0tN2FXckNuSEtXZy1yc1NsR05OTnFuQW9BNzhGb3haUXlEVHRKVEFNV0NkUi1xMG1oMlcxUURTbFFSdlFRdVVBYURTVWFTNDRCbFR0SmM0S3hDQ2pPSWRhckVjS1E2bg?oc=5","date":"2023-12-13","type":"pipeline","source":"SCIRP Open Access","summary":"Persistence of Healthcare-Associated (Nosocomial) Infections Due to Inadequate Hand Hygiene Part 1—Biological and Treatment Factors - SCIRP Open Access","headline":"Persistence of Healthcare-Associated (Nosocomial) Infections Due to Inadequate Hand Hygiene Part 1—Biological and Treatm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5mbmI1MzVfclc3a2FsWmZjR0R2cDltNkxTZzNKV0doSktBZXNxS3M2bXFPM0syRDJHVms1NWJGTVYwRFZBMzJ4eU9xTVhDRGg3b25HUnlMdGotTERoTWc5SnpiMUR5QVBKNV94NQ?oc=5","date":"2023-12-11","type":"pipeline","source":"SCIRP Open Access","summary":"Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine - SCIRP Open Access","headline":"Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1MU0hZRHZvTlBEclUzeVNEMTBEckpMODFZakV4d0twaHduNk8tSzdvc0VxQ01qenNQX240czFtb2xvUXJ4UzNPVUg1Z3ZoVWlQUEwzR0JmWG5xMGJheW9OaEdTSTFZMmk3RjZiTA?oc=5","date":"2023-12-10","type":"regulatory","source":"SCIRP Open Access","summary":"The First Approved “Deuterated” Drug: A Short Review of the Concept - SCIRP Open Access","headline":"The First Approved “Deuterated” Drug: A Short Review of the Concept","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}